These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 2981393)

  • 1. Problems in the contemporary treatment of parkinsonism.
    Eadie MJ
    Med J Aust; 1985 Jan; 142(2):113-7. PubMed ID: 2981393
    [No Abstract]   [Full Text] [Related]  

  • 2. [Extrapyramidal and presenile dementia. Relation between symptoms of dementia and cerebral transmitters, particularly dopamine].
    Kristensen V
    Ugeskr Laeger; 1976 Aug; 138(34):2047-50. PubMed ID: 184570
    [No Abstract]   [Full Text] [Related]  

  • 3. Synaptic plasticity, dopamine and Parkinson's disease: one step ahead.
    Calabresi P; Mercuri NB; Di Filippo M
    Brain; 2009 Feb; 132(Pt 2):285-7. PubMed ID: 19168452
    [No Abstract]   [Full Text] [Related]  

  • 4. [Biochemistry of neuronal transmission. Pharmacology of parkinsonism].
    Lombardo L
    Gac Med Mex; 1981 Dec; 117(12):476-8. PubMed ID: 6123462
    [No Abstract]   [Full Text] [Related]  

  • 5. Peculiarities of L: -DOPA treatment of Parkinson's disease.
    Kostrzewa RM; Nowak P; Kostrzewa JP; Kostrzewa RA; Brus R
    Amino Acids; 2005 Mar; 28(2):157-64. PubMed ID: 15750845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological basis of akinesia in Parkinson's disease.
    Narabayashi H
    J Neural Transm Suppl; 1983; 19():143-51. PubMed ID: 6583305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiology of the normal and dopamine-depleted basal ganglia: insights into levodopa pharmacotherapy.
    Grace AA
    Mov Disord; 2008; 23 Suppl 3():S560-9. PubMed ID: 18781673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Thoughts on the neurobiological aspects of Parkinson syndrome].
    Sommer H
    Psychiatr Neurol Med Psychol (Leipz); 1986 Feb; 38(2):86-90. PubMed ID: 3010357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disorders.
    Di Matteo V; Pierucci M; Esposito E; Crescimanno G; Benigno A; Di Giovanni G
    Prog Brain Res; 2008; 172():423-63. PubMed ID: 18772045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-induced changes in brain dopamine and their relation to parkinsonism.
    Vogt M
    Sci Basis Med Annu Rev; 1970; ():276-91. PubMed ID: 4319923
    [No Abstract]   [Full Text] [Related]  

  • 11. [Cerebral hemodynamics and clinical pharmacology in Parkinson disease].
    Marc-Vergnes JP; Celsis P; Montastruc JL; Demonet JF; Agniel A; Rascol O; Viallard G; Doyon B; Rascol A
    Therapie; 1988; 43(2):83-8. PubMed ID: 3406932
    [No Abstract]   [Full Text] [Related]  

  • 12. Mapping neuronal activity of the basal ganglia in experimental models of Parkinson's disease: contributions of the [14C]2-deoxyglucose method.
    Orzi F; Fornai F; Blandini F
    Funct Neurol; 2000; 15(4):269-76. PubMed ID: 11213530
    [No Abstract]   [Full Text] [Related]  

  • 13. [Movement disorders and basal ganglia function].
    Dietrichs E
    Tidsskr Nor Laegeforen; 2008 Sep; 128(17):1968-71. PubMed ID: 18787574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developments in understanding the physiology and pharmacology of parkinsonism.
    Teräväinen H; Calne DB
    Acta Neurol Scand; 1979 Jul; 60(1):1-11. PubMed ID: 40381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The history of dopamine and levodopa in the treatment of Parkinson's disease.
    Fahn S
    Mov Disord; 2008; 23 Suppl 3():S497-508. PubMed ID: 18781671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine receptors in the basal ganglia: relevance to Parkinson's disease.
    Strange PG
    Mov Disord; 1993 Jul; 8(3):263-70. PubMed ID: 8101967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Levodopa as a single treatment of Parkinsonism. Long-term control of 24 cases with discrimination analysis].
    Borromei A; Manzini A
    Minerva Med; 1974 Nov; 65(79):4160-70. PubMed ID: 4610450
    [No Abstract]   [Full Text] [Related]  

  • 18. Three types of akinesia in the progressive course of Parkinson's disease.
    Narabayashi H
    Adv Neurol; 1993; 60():18-24. PubMed ID: 8093577
    [No Abstract]   [Full Text] [Related]  

  • 19. Problems arising during chronic treatment with L-dopa for Parkinson's disease: changes in response to treatment.
    Caraceni TA; Girotti F; Giovannini P; Parati E
    J Neural Transm Suppl; 1986; 22():189-99. PubMed ID: 3537210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Parkinson disease--a movement disorder].
    Fortschr Neurol Psychiatr; 1997 Apr; 65(4 Suppl Morbus):1-4. PubMed ID: 9330648
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.